Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by PDT Partners LLC

PDT Partners LLC boosted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 7.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 248,607 shares of the company’s stock after buying an additional 18,130 shares during the quarter. PDT Partners LLC owned 0.54% of Pacira BioSciences worth $4,684,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. ExodusPoint Capital Management LP grew its position in shares of Pacira BioSciences by 232.6% in the 4th quarter. ExodusPoint Capital Management LP now owns 212,824 shares of the company’s stock worth $4,010,000 after acquiring an additional 148,842 shares in the last quarter. Northern Trust Corp grew its position in shares of Pacira BioSciences by 30.8% in the 4th quarter. Northern Trust Corp now owns 616,891 shares of the company’s stock worth $11,622,000 after acquiring an additional 145,205 shares in the last quarter. Norges Bank acquired a new position in Pacira BioSciences during the 4th quarter valued at approximately $2,405,000. Natixis acquired a new position in Pacira BioSciences during the 4th quarter valued at approximately $1,738,000. Finally, Charles Schwab Investment Management Inc. boosted its position in Pacira BioSciences by 16.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock valued at $9,462,000 after purchasing an additional 70,307 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Trading Up 5.5 %

PCRX stock opened at $27.14 on Tuesday. The company has a market capitalization of $1.26 billion, a PE ratio of -13.37 and a beta of 0.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The company’s 50-day simple moving average is $24.52 and its 200 day simple moving average is $21.61.

Analyst Ratings Changes

PCRX has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $32.00 price objective on shares of Pacira BioSciences in a research report on Tuesday, April 8th. HC Wainwright lifted their target price on Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a research note on Tuesday, April 8th. Barclays lifted their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, February 28th. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price objective for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Pacira BioSciences presently has a consensus rating of “Hold” and an average price target of $26.67.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.